Pfizer to close Australia plant, whack 89 jobs

Pfizer
Pfizer will close a plant in Australia where 89 workers currently work.

It's a reversal of fortunes for a Pfizer plant in Australia. The U.S. drugmaker has decided to close the facility and lay off nearly 90 workers after announcing expansion plans for the site a year ago.

Pfizer has announced it will close the plant in Adelaide by the end of 2021 as it again consolidates its manufacturing, ABC News in Australia reported. The plant currently has 89 workers.

"This has been a difficult decision, and was based on a number of factors including the existing capacity within Pfizer's global manufacturing network and the efficiency of consolidating manufacturing to fewer locations," the company said in a statement, the news site reported.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

The drugmaker announced in March last year it would invest about $15.7 million (AU$21 million) to expand the capacity at the Adelaide plant that makes pegfilgrastim, the active ingredient for Amgen’s cancer drug Neulasta.

It is the second Pfizer plant in Australia to be slated for closure in recent years. The drugmaker in 2015 closed a plant in Sydney, laying off about 140 workers.

Read more on

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.